Harvard Bioscience reports company news on its life science research tools business, which develops, manufactures and sells technologies, products and services for research, pharmaceutical and therapy discovery, bioproduction and preclinical testing. Updates commonly cover operating and financial results, new products for translational science, New Approach Methodologies, product mix, and customer markets that include academic institutions, government laboratories, pharmaceutical companies, biotechnology companies and contract research organizations.
Company releases also address capital actions, Nasdaq listing compliance, manufacturing and operating-model changes, management appointments, guidance, and investor conference presentations. The business sells through direct and distribution channels and has operations in the United States, Europe and China.
Harvard Bioscience (NASDAQ: HBIO) announced a 1-for-10 reverse stock split approved March 6, 2026, effective 4:30 p.m. ET on March 13, 2026, with post-split trading expected March 16, 2026.
The Reverse Split will convert every ten shares into one, reduce outstanding shares from ~44,719,894 to ~4,471,989, leave total authorized shares unchanged, and proportionally adjust options, warrants, and convertible securities.
No fractional shares will be issued; fractional holders will receive cash in lieu based on the March 13, 2026 closing price as adjusted for the split.
Harvard Bioscience (Nasdaq: HBIO) announced that CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17, 2026.
A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET, with an audio-only webcast option available via the events and presentations section.
Harvard Bioscience (Nasdaq: HBIO) will announce financial results for the quarter ended December 31, 2025 before the market opens on March 12, 2026.
The company will host an earnings conference call at 8:00 AM Eastern Time; registration is required for participants who wish to ask questions and an audio-only webcast will be available on the investor website.
Harvard Bioscience (NASDAQ: HBIO) reported preliminary Q4 2025 results and outlined a long-term translational science strategy. Q4 revenue $23.7M (above midpoint), gross margin 60% (high end) and adjusted EBITDA $3.8M (+27% YoY). The company targets year‑over‑year revenue growth and mid‑to‑high single‑digit EBITDA growth in 2026 while prioritizing new high‑margin platforms, consumables expansion (55% recurring mix) and operational consolidation, supported by recent debt refinancing and U.S. manufacturing consolidation. Full FY2025 results and a conference call are scheduled for March 12, 2026.
Harvard Bioscience (Nasdaq: HBIO) announced a strategic consolidation of manufacturing to improve efficiency and support long-term growth. The Company will close its Holliston, MA plant, shift U.S. production to Minneapolis, and relocate certain operations to Germany, Sweden, and the UK.
The Holliston site will operate through 2026 with completion targeted by Q1 2027. The initiative is expected to yield approximately $3 million in savings in 2027 and about $4 million in annual savings thereafter, while generating transition-related operating expenses in 2026 and early 2027.
Harvard Bioscience (NASDAQ: HBIO) completed a refinancing and secured a $40.0 million credit facility from BroadOak on Dec 17, 2025 to repay existing debt, strengthen liquidity and extend maturities.
The package includes Term Loan A & B totaling $32.5M, and Term Loan C of $7.5M convertible at $1.00 per share; all loans mature on Dec 17, 2029. Quarterly amortization begins Dec 31, 2027. BroadOak received warrants for 2.0M shares at $0.50 and a board nomination; Bill Snider joined the board effective Dec 17, 2025.
Harvard Bioscience (Nasdaq: HBIO) reported Q3 2025 revenue of $20.6M, gross margin of 58.4%, and a net loss of $1.2M. Adjusted EBITDA for Q3 was $2.0M and cash provided by operations was $1.1M. For the nine months ended Sept 30, 2025, revenue was $62.8M and net loss was $53.8M, driven primarily by a $48.0M goodwill impairment in Q1. The company says it expects to refinance or repay its credit agreement in Q4 2025 and provided Q4 2025 guidance of $22.5M–$24.5M revenue with gross margin of 58%–60%.
The company also reported the highest backlog in nearly two years and four consecutive months of order growth, and will host a webcast and conference call on Nov 6, 2025.
Harvard Bioscience (NASDAQ: HBIO) will report financial results for the quarter ended September 30, 2025 before market open on November 6, 2025. The company will host a conference call to discuss results at 8:00 AM Eastern Time on the same day.
Participants who wish to ask questions must register to receive dial-in numbers and a unique PIN. An audio-only webcast will be available via the company’s Investor Relations events and presentations page. The earnings release and related slide presentation will be posted in the Investor Relations section.
Harvard Bioscience (Nasdaq: HBIO) has expanded its distribution agreement with Fisher Scientific to include the United States market, building upon their existing European partnership. The expanded agreement enables Fisher Scientific to distribute Harvard Bioscience's pumps, spectrophotometers, and BTX electroporation systems throughout the U.S.
The strategic expansion gives Harvard Bioscience access to hundreds of Fisher Scientific sales representatives and their extensive U.S. distribution network. The partnership will offer both established product lines and emerging technologies, including the Mesh MEA for advanced organoid research. This collaboration aims to enhance customer experience through streamlined ordering, faster delivery, and localized support.
Harvard Bioscience (Nasdaq: HBIO) has announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. DeNelsky, who brings 30 years of healthcare industry experience, will serve on the Board's Nominating and Governance Committee.
Currently serving as Managing Director at Oaktree Capital Management, DeNelsky has extensive experience in research, analysis, and valuation of healthcare equities. He also serves on the board of Visioncare Inc and previously held board positions at Integrated Diagnostics and AMICAS, Inc. His expertise spans life sciences, pharmaceuticals, devices, and services sectors.